about
Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1)CixutumumabRetroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo.Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection PathwaysFunctional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancersCrystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificitySmall-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptorETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylationGain of allelic gene expression for IGF-II occurs frequently in Barrett's esophagusAMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathwaysSimultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.Insulin-like growth factor 1 receptor is a prognostic factor in classical Hodgkin lymphoma.Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization.Role of ubiquitination in IGF-1 receptor signaling and degradation.A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.SCF, BDNF, and Gas6 are regulators of growth plate chondrocyte proliferation and differentiation.The complexity of the IGF1 gene splicing, posttranslational modification and bioactivityPTK6 regulates IGF-1-induced anchorage-independent survival.Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic indexIGF-IR internalizes with Caveolin-1 and PTRF/Cavin in HaCat cells.The IGF axis and hepatocarcinogenesis.Insulin-like growth factor 1 (IGF-1): a growth hormoneATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response.Gene expression analysis of pancreatic cystic neoplasm in SV40Tag transgenic mice model.Pediatric brain tumor treatment: growth consequences and their managementThe mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase.Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy.Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells.Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinasesWISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancerPhysical and functional interaction between polyoma virus middle T antigen and insulin and IGF-I receptors is required for oncogene activation and tumour initiation.Inhibition of IGF-1R prevents ionizing radiation-induced primary endothelial cell senescenceThe role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy.Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay.Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signalingIGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report
P2860
Q24293531-52FA704F-BA05-40C8-93A2-B3D02E716CE7Q24609058-0C9D1771-C667-48E9-A1AD-45BF9871ADE7Q24794042-11E9B125-FED7-4A8A-8E3D-55FF3108EBF3Q26742114-7DE5ABE5-FC85-40DE-8D71-DCFFE1E02296Q26830002-B477F5DE-DDB9-4351-884E-4AA86520D117Q27639414-30663F71-7691-49F5-A6A1-9BB96527B4BEQ27650906-5C6AF2BB-4B58-4B07-A0FE-14DD00478B69Q28217452-D5364B2D-F666-469B-86CB-98B80190EC20Q28285950-724E61F5-09F4-48BD-8C62-672DEC3DA323Q30412634-840BF8F7-A5FB-4793-9438-82D4322B0CFDQ31016741-7E2A2894-4F5E-4715-9860-2D5962DB3074Q31149390-A00DC1DD-1AA9-4194-BB62-7C621409342BQ33232494-91DBA519-1305-4464-80F4-FCA3854359EDQ33280993-2E52EF9F-E0CB-483E-96FA-EFEFA6AE9253Q33418329-9C2C3C59-B0A1-4E99-8440-072D39BAAA7FQ33576515-BC9043CE-98FA-4DF6-910E-91D029F3BB04Q33619027-722E73AC-8B3C-4700-961A-B12CDF42429AQ33644326-469F8BF6-2AF0-421B-A8E8-C8C2729CD535Q33718131-FC36EE7F-B8F4-488C-BD57-45068BC86747Q33770174-36417D8B-ABA3-45C6-88F9-C4EFC7D06672Q33918694-9BB038DC-CABA-44B5-8DA7-D6B4991F9220Q33918809-3DEE681F-D815-4156-9AB6-7B09D4EB1D04Q34098413-99647B0F-973D-4812-9E75-63A738E12D3FQ34098921-5FB07E30-F087-467C-996B-FFEA1419771CQ34106670-19F2A88E-B207-4EC0-B029-59359B2261F4Q34273711-50424EE5-4BBB-4280-9F7E-6398BD528652Q34659512-DAA206BE-02DD-45D0-B6F8-BBF411ECEBFEQ34679398-DCB36BF9-46A3-46FE-9308-2CDA04ADB531Q34695649-32DCD8F5-9BDE-446E-A05A-6F84B4054B80Q34743655-4F69CDFA-0089-4C1B-B3B3-D525D9670799Q34770011-7DA01994-0E67-44F8-833F-109AB567ED3FQ34993028-0FAC5A80-2E45-4F68-AA4D-F5222F4EA063Q35036570-E2C14F6B-74F8-4DFB-9D0C-0955E58F9ED0Q35094666-5865BF36-7391-42DD-8058-71A49A207378Q35130223-BDFAC8A4-EC72-4EC2-AD3C-8B3703A4E7BBQ35597311-17A4657B-0FD9-4EA4-A063-B97E1F64D238Q35609517-2EA1FD3A-E57E-4886-8100-345840486C06Q35677661-F5897024-7F8A-4461-A981-EF2E57E51078Q35774487-59639A0A-2CB4-424B-8C88-F08963252428Q36121569-CAA2E33A-0F21-41AF-9D39-B200A5F5F0AC
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The IGF-I receptor in cancer research.
@ast
The IGF-I receptor in cancer research.
@en
type
label
The IGF-I receptor in cancer research.
@ast
The IGF-I receptor in cancer research.
@en
prefLabel
The IGF-I receptor in cancer research.
@ast
The IGF-I receptor in cancer research.
@en
P356
P1476
The IGF-I receptor in cancer research.
@en
P2093
P356
10.1006/EXCR.1999.4667
P407
P577
1999-11-01T00:00:00Z